BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Coimbra FJF, de Jesus VHF, Ribeiro HSC, Diniz AL, de Godoy AL, de Farias IC, Felismino T, Mello CAL, Almeida MF, Begnami MDFS, Dias-Neto E, Riechelmann RSP, da Costa WL Jr. Impact of ypT, ypN, and Adjuvant Therapy on Survival in Gastric Cancer Patients Treated with Perioperative Chemotherapy and Radical Surgery. Ann Surg Oncol 2019;26:3618-26. [PMID: 31222685 DOI: 10.1245/s10434-019-07454-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Coimbra FJF, da Costa WL Jr. ASO Author Reflections: High-Quality Perioperative and Surgical Therapy: The Impact of Tumor Response in Survival. Ann Surg Oncol 2020;27:729-30. [PMID: 32661857 DOI: 10.1245/s10434-019-07959-8] [Reference Citation Analysis]
2 Sakin A, Atci MM, Aldemir MN, Akagündüz B, Şahin S, Arıcı S, Secmeler S, Cihan S. The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy. Cureus 2021;13:e14639. [PMID: 34046274 DOI: 10.7759/cureus.14639] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chen Y, Wei K, Liu D, Xiang J, Wang G, Meng X, Peng J. A Machine Learning Model for Predicting a Major Response to Neoadjuvant Chemotherapy in Advanced Gastric Cancer. Front Oncol 2021;11:675458. [PMID: 34141620 DOI: 10.3389/fonc.2021.675458] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Ballhausen A, Bartels P, Iacovella I, Hoegner A, Lorusso A, Bichev D, Daum S, Thuss-patience P. Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy. Current Oncology 2022;29:1983-96. [DOI: 10.3390/curroncol29030161] [Reference Citation Analysis]
5 Galata C, Blank S, Weiss C, Ronellenfitsch U, Reissfelder C, Hardt J. Role of Postoperative Complications in Overall Survival after Radical Resection for Gastric Cancer: A Retrospective Single-Center Analysis of 1107 Patients. Cancers (Basel) 2019;11:E1890. [PMID: 31783704 DOI: 10.3390/cancers11121890] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Castro JSL, Pelosof AG, Andrade-Cabral JGG, Seraphim AM, Taglieri E, Coimbra FJF, Zitron C. ENDOSCOPIC CHARACTERISTICS OF PATIENTS WITH COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY FOR GASTRIC AND ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMAS. Arq Bras Cir Dig 2022;34:e1616. [PMID: 35019128 DOI: 10.1590/0102-672020210002e1616] [Reference Citation Analysis]
7 Arigami T, Matsushita D, Okubo K, Sasaki K, Noda M, Kita Y, Mori S, Kurahara H, Yanagita S, Uenosono Y, Ishigami S, Ohtsuka T. Prognostic impact of surgery after chemotherapy for type 4 gastric cancer. Surg Today 2021. [PMID: 34115210 DOI: 10.1007/s00595-021-02320-7] [Reference Citation Analysis]
8 Tong G, Li S, Lin L, He L, Wang L, Lv G, Zheng R, Wang S. Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study. Cancer Manag Res 2020;12:2481-9. [PMID: 32308484 DOI: 10.2147/CMAR.S239420] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Bartelli TF, Senda de Abrantes LL, Freitas HC, Thomas AM, Silva JM, Albuquerque GE, Araújo LF, Branco GP, de Amorim MG, Serpa MS, Takenaka IKTM, Souza DT, Monção LO, Moda BS, Valieris R, Defelicibus A, Borges R, Drummond RD, Alves FIA, Santos MNP, Bobrovnitchaia IG, Elhaik E, Coelho LGV, Khayat A, Demachki S, Assumpção PP, Santiago KM, Torrezan GT, Carraro DM, Peres SV, Calsavara VF, Burbano R, Nóbrega CR, Baladão GPP, Pereira ACC, Gatti CM, Fagundes MA, Araújo MS, Miranda TV, Barbosa MS, Cardoso DMM, Carneiro LC, Brito AM, Ramos AFPL, Silva LLL, Pontes JC, Tiengo T, Arantes PE, Santana V, Cordeiro M, Sant’ana RO, Andrade HB, Anaissi AKM, Sampaio SV, Abdallah EA, Chinen LTD, Braun AC, Flores BCT, Mello CAL, Claro LCL, Sztokfisz CZ, Altamirano CC, Carter DRF, Jesus VHF, Riechelmann R, Medina T, Gollob KJ, Martins VR, Setúbal JC, Pelosof AG, Coimbra FJ, Costa-jr WL, Silva IT, Nunes DN, Curado MP, Dias-neto E; GE4GAC group. Genomics and epidemiology for gastric adenocarcinomas (GE4GAC): a Brazilian initiative to study gastric cancer. Appl Cancer Res 2019;39. [DOI: 10.1186/s41241-019-0081-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Shannon AB, Straker RJ 3rd, Keele L, Fraker DL, Roses RE, Miura JT, Karakousis GC. Lymph Node Evaluation after Neoadjuvant Chemotherapy for Patients with Gastric Cancer. Ann Surg Oncol 2021. [PMID: 34601642 DOI: 10.1245/s10434-021-10803-7] [Reference Citation Analysis]
11 Slagter AE, Vollebergh MA, Jansen EPM, van Sandick JW, Cats A, van Grieken NCT, Verheij M. Towards Personalization in the Curative Treatment of Gastric Cancer. Front Oncol. 2020;10:614907. [PMID: 33330111 DOI: 10.3389/fonc.2020.614907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Liu Z, Wang Y, Shan F, Ying X, Zhang Y, Li S, Jia Y, Li Z, Ji J. 5-Fu-Based Doublet Regimen in Patients Receiving Perioperative or Postoperative Chemotherapy for Locally Advanced Gastric Cancer: When to Start and How Long Should the Regimen Last? Cancer Manag Res 2021;13:147-61. [PMID: 33469359 DOI: 10.2147/CMAR.S285361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Tong Y, Zhao Y, Shan Z, Zhang J. CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy. BMC Cancer 2021;21:4. [PMID: 33402124 DOI: 10.1186/s12885-020-07666-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]